• 1. Ultrasound-assisted cloud point extraction for the determination of sulfonamides in honey samples by fluorescence spectrophotometry
  Fang Yu,Chang Liu,Yuhong Guo,Yaling Yang Anal. Methods 2013 5 3920
• 2. Antiproliferative activity and conversion of tachyzoite to bradyzoite of Toxoplasma gondii promoted by new zinc complexes containing sulfadiazine
  Luana C. Batista,Fernanda S. de Souza,Vagner M. de Assis,Sérgio H. Seabra,Adailton J. Bortoluzzi,Magdalena N. Rennó,Adolfo Horn,Renato A. DaMatta,Christiane Fernandes RSC Adv. 2015 5 100606
• 3. Green electrochemical synthesis of silver sulfadiazine microcrystals
  Faezeh Zivari Moshfegh,Mahmood Masoudi Khoram,Davood Nematollahi RSC Adv. 2019 9 24105
• 4. One-pot sustainable synthesis of magnetic MIL-100(Fe) with novel Fe3O4 morphology and its application in heterogeneous degradation
  Huairu Tian,Jun Peng,Qiuzheng Du,Xuanhong Hui,Hua He Dalton Trans. 2018 47 3417
• 5. Hybrid CuCoO–GO enables ultrasensitive detection of antibiotics with enhanced laser desorption/ionization at nano-interfaces
  Enhui Wu,Kun Feng,Rui Shi,Rui Lv,Fuzhong Ouyang,Shawn S. C. Li,Jun Zhong,Jian Liu Chem. Sci. 2019 10 257

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzenesulfonamides
• Solvents and Organic Chemicals Organic Compounds Amines/Sulfonamides

Introduction to Sulfadiazine sodium (CAS No: 547-32-0)

Sulfadiazine sodium, with the chemical formula NaC?H?N?O?S, is a well-established sulfonamide derivative that has garnered significant attention in the field of pharmaceutical chemistry and medicine. This compound, identified by its CAS number 547-32-0, is primarily recognized for its therapeutic applications, particularly in the treatment of various bacterial infections. The sodium salt form of sulfadiazine enhances its solubility, making it more suitable for intravenous and oral administration, thereby improving its bioavailability and therapeutic efficacy.

The sulfonamide class of drugs, to which Sulfadiazine sodium belongs, operates by inhibiting the enzyme dihydropteroate synthase (DHPS), which is crucial for the synthesis of para-aminobenzoic acid (PABA) in bacteria. PABA is an essential component in the production of folic acid, a vital nutrient for bacterial growth and replication. By blocking PABA synthesis, Sulfadiazine sodium effectively disrupts bacterial metabolism and proliferation, leading to a reduction in bacterial population and subsequent resolution of infections.

In recent years, Sulfadiazine sodium has been explored for its potential in managing specific clinical conditions. One notable area of research involves its application in the treatment of neuroinvasive infections caused by *Neisseria meningitidis*. Studies have demonstrated that Sulfadiazine sodium, when used as part of a combination therapy regimen, can significantly reduce the mortality rate associated with meningococcal meningitis. The ability of this compound to cross the blood-brain barrier makes it particularly valuable in addressing infections that affect the central nervous system.

Moreover, research has highlighted the synergistic effects of Sulfadiazine sodium when combined with other antibiotics. For instance, studies have shown that co-administration of Sulfadiazine sodium with beta-lactam antibiotics can enhance the overall efficacy against multidrug-resistant bacterial strains. This combination therapy approach is particularly relevant in today's healthcare landscape, where antibiotic resistance poses a significant challenge to effective infection management.

The pharmacokinetic profile of Sulfadiazine sodium has also been extensively studied to optimize its therapeutic use. The compound exhibits moderate oral bioavailability and a relatively long half-life, allowing for once or twice daily dosing schedules. This characteristic makes it convenient for patient compliance and reduces the frequency of administration required for maintaining therapeutic levels in the bloodstream.

Recent advancements in drug delivery systems have further expanded the applications of Sulfadiazine sodium. Nanoparticle-based formulations have been developed to improve drug solubility and target specificity, enhancing both efficacy and safety. These novel delivery systems hold promise for treating infections that are difficult to manage with conventional formulations.

The safety profile of Sulfadiazine sodium is well-documented, with common side effects including gastrointestinal disturbances such as nausea and diarrhea. However, serious adverse effects are relatively rare when used at appropriate doses under medical supervision. Long-term studies have not identified significant organ toxicity or carcinogenic potential associated with its use.

In conclusion, Sulfadiazine sodium (CAS No: 547-32-0) remains a valuable therapeutic agent in modern medicine. Its broad-spectrum antimicrobial activity, combined with recent innovations in drug delivery and combination therapy strategies, underscores its continued relevance in addressing bacterial infections. As research progresses, further applications and refinements in its use are expected to emerge, solidifying its role as a cornerstone in antimicrobial chemotherapy.

• 7470-75-9(3-Amino-N-(pyrimidin-2-yl)benzene-1-sulfonamide)
• 17103-46-7(4-amino-N-(1H-imidazol-2-yl)Benzenesulfonamide,)
• 599-88-2(4-Amino-N-(5-methylpyrimidin-2-yl)benzenesulfonamide)
• 64047-46-7(Benzenesulfonamide,4-isothiocyanato-N-2-pyrimidinyl-)
• 3271-01-0(Benzenesulfonamide,4-amino-N-(5-ethyl-2-pyrimidinyl)-)
• 5414-66-4(Benzenesulfonamide,4-amino-N-(5-bromo-2-pyrimidinyl)-)
• 16699-12-0(2-Benzenesulfonamidopyrimidine)
• 68-35-9(Sulfadiazine)
• 22199-08-2(Silver sulfadiazine)
• 61567-34-8(Silver(1+), (4-amino-N-2-pyrimidinylbenzenesulfonamide)-, nitrate)